NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
Clinical Trials
9 trialsNCT05976568 2023-08-04
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Not yet recruiting
NCT02069041 2018-11-21
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02089633 2017-07-28
PACOX
Bio-Cancer Treatment International Limited
Phase 2 Completed
NCT00861783 2017-06-23
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
Traws Pharma, Inc.
Phase 1 Completed
NCT01245582 2011-11-09
SECOX
Sanofi
Phase 3 Withdrawn
NCT00559455 2011-06-28
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
Sanofi
Phase 2 Completed
NCT00471965 2010-09-20
EACH
Sanofi
Phase 3 Completed
NCT00280618 2009-09-15
Oxaliplatin in Unresectable Hepatocellular Carcinoma
Sanofi
Phase 2 Completed